GleamWall
中文EN

ANIP ANI PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1023024 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY25.9%
TTM net income YoY188.0%
TTM EPS YoY214.4%
Revenue 3-yr CAGR32.3%
Net income 3-yr CAGR105.9%

Margins

Gross margin61.1%
Operating margin16.0%
Net margin11.2%
FCF margin19.7%
EBITDA margin23.9%

Returns

ROE20.4%
ROA7.9%
ROIC (approx.)23.0%
Asset turnover0.70x

Leverage & solvency

Liabilities / assets59.4%
Debt / equity0.47x
Current ratio2.75x
Interest coverage5.44x

Cash quality & payout

Operating cash flow / net income1.96x
Accruals ratio-7.6%
Payout ratio0.0%
Capex / revenue2.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$883.37M$614.38M
Cost of revenue$341.31M$250.21M
Gross profit$542.06M$364.17M
R&D expense$51.66M$44.58M
SG&A expense$317.75M$249.64M
Operating income$111.09M$584,000
Interest expense$32.56M$33.63M
Pretax income$95.79M-$22.21M
Income tax$17.45M-$3.69M
Net income$78.34M-$18.52M
EBITDA$202.51M$68.31M
EPS (basic)3.50-1.04
EPS (diluted)3.32-1.04
Weighted avg. shares (diluted)21.23M19.32M
Balance sheet
Cash & equivalents$285.58M$144.86M
Receivables$281.08M$221.73M
Inventory$143.07M$136.78M
Current assets$753.12M$528.46M
PP&E, net$62.48M$56.86M
Goodwill$62.48M$59.99M
Intangibles$479.53M$541.83M
Total assets$1.44B$1.28B
Current liabilities$278.11M$194.45M
Short-term debt$17.27M$9.17M
Long-term debt$291.84M$309.11M
Total debt$309.11M$318.28M
Total liabilities$899.65M$855.94M
Shareholders' equity$540.72M$403.68M
Net debt$23.52M$173.42M
Shares outstanding22.49M21.11M
Cash flow statement
Operating cash flow$185.22M$64.02M
Capital expenditure$13.84M$16.24M
Free cash flow$171.39M$47.78M
Investing cash flow-$34.32M-$404.72M
Financing cash flow-$9.94M$264.94M
Depreciation & amortization$91.42M$67.73M
Stock-based compensation$37.93M$29.34M
Dividends paid$1.16M$1.62M
Share buybacks$12.21M$10.96M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.